Skye Bioscience, Inc. Earnings Recaps
Q3 2025
Nov 11, 2025
Skye Bioscience, Inc. delivered promising data from its Phase 2a CBEYOND study, demonstrating strong efficacy of Nimazumab in combination with semaglutide and reporting a net loss of $12.8 million for Q3 2025.
Key takeaways
- Cash reserves stood at $35.3 million, expected to fund operations through 2027.
- R&D expenses rose to $9.4 million, reflecting increased clinical trial activity and manufacturing costs.
- Positive findings from the CBEYOND study revealed a 30% improvement in weight loss efficacy when combining Nimazumab with semaglutide.
- Data also demonstrated enhanced metabolic benefits and safety with no significant adverse effects observed.
- Enrollment in a 26-week extension study was completed, with results anticipated by late Q1 2026.